Since cancer cells with BRCA1 mutations mostly rely on PARP1 to repair damaged DNA for survival, PARP inhibitors can sensitize the cancer cells inducing synthetic lethality (Tangutoori et al., 2015; Faraoni and Graziani, 2018). Here, PARP1 is linked to cancer.